Chattem has acquired three personal care and two healthcare brands from Johnson & Johnson. The two companies announced the closing of the deal on Jan. 2, 2007 for a reported $410 million in cash. Chattem now has the rights to Act, Cortizone, Balmex, Unisom and Kaopectate. The five brands were part of Johnson & Johnson's acquisition of Pfizer's Consumer Healthcare business, which J&J reportedly had to sell to comply with regulatory requirements.
Chattem's personal care portfolio, in addition to the new brands, includes names such as Sportscreme, Aspercreme, Gold Bond, Selsun Blue, Sun-In and UltraSwim. The company reportedly plans to explore the growth potential of its newly acquired brands.
Chattem's personal care portfolio, in addition to the new brands, includes names such as Sportscreme, Aspercreme, Gold Bond, Selsun Blue, Sun-In and UltraSwim. The company reportedly plans to explore the growth potential of its newly acquired brands.